Nasopharyngeal Cancer: New Frontiers From the Laboratory to the Clinic
- Division of Applied Molecular Oncology, Ontario Cancer Institute, University Health Network, Toronto, Ontario (Canada)
Nasopharyngeal carcinoma (NPC) is a unique malignant epithelial carcinoma of the head-and-neck region, with unique viral biology and geographic distributions in the world. Significant advances have been made in the clinical therapies for NPC, with novel techniques for radiation delivery and randomized trials demonstrating the survival advantage of concurrent chemotherapy for patients with locally advanced diseases. At the same time, there has been an improved understanding of the molecular dysregulations underpinning this disease, with recent discoveries emerging from the use of high-throughput technologies, including microarray expression profiling and robotic screens of chemical libraries. Signaling pathways related to cell renewal, proliferation, and apoptosis are important cascades, which could offer potentially novel strategies to develop targeted therapies, with the ultimate aim to improve outcome for future patients with NPC.
- OSTI ID:
- 21036284
- Journal Information:
- International Journal of Radiation Oncology, Biology and Physics, Vol. 69, Issue 2; Conference: Inaugural multidisciplinary head and neck cancer symposium, Rancho Mirage, CA (United States), 18-20 Jan 2007; Other Information: DOI: 10.1016/j.ijrobp.2007.05.070; PII: S0360-3016(07)00992-3; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
- Country of Publication:
- United States
- Language:
- English
Similar Records
Nasopharyngeal Carcinoma Treated With Reduced-Volume Intensity-Modulated Radiation Therapy: Report on the 3-Year Outcome of a Prospective Series
miR-9 modulates the expression of interferon-regulated genes and MHC class I molecules in human nasopharyngeal carcinoma cells